Drug intelligence / Profile preview

Ascendra

Development stage: Unknown
Lead developer: anwerina Deutschland
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Intranasal

Overview

Ascendra is an intranasal powder formulation of teriparatide, a recombinant human parathyroid hormone (PTH 1-34), developed by the Japanese biotechnology company Anwerina. It is primarily indicated for the treatment of osteoporosis. As an anabolic bone agent, teriparatide works by binding to and activating the parathyroid hormone receptor 1 (PTH1R), which stimulates osteoblast activity and increases bone formation. Ascendra is designed to provide a non-invasive alternative to the standard subcutaneous injections of teriparatide, potentially enhancing patient adherence and convenience through its nasal delivery system.

Brand names: Ascendra
Other names: teriparatide nasal powder

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)

Beyond the preview

Go deeper on Ascendra.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ascendra.

Explore the full profile